Literature DB >> 25356924

Long-term outcomes and patterns of failure in orbital lymphoma treated with primary radiotherapy.

Rahul R Parikh1, Bruce K Moskowitz, Elizabeth Maher, David Della Rocca, Robert Della Rocca, Bruce Culliney, Ilan Shapira, Michael L Grossbard, Louis B Harrison, Kenneth Hu.   

Abstract

The purpose of this study was to evaluate the long-term outcome and patterns of failure in patients treated with primary radiotherapy (RT) for orbital lymphoma (OL). Seventy-nine patients diagnosed with stage IE OL between 1995 and 2012 were included. Fifty-nine patients (75%) had mucosa-associated lymphoid tissue lymphoma and 20 patients (25%) had follicular lymphoma subtype. The median follow-up was 49.7 months. Major tumor sites were conjunctiva (29%), orbit (47%) and lacrimal gland (24%). After treatment to a median dose of 30.6 Gy, there were a total of no local, one contralateral orbital, two regional and two distant recurrences, all outside of the treatment fields. The 10-year local relapse-free, distant metastasis-free and overall survival rates were 100%, 94.2% and 98.2%, respectively. Definitive RT to 30 Gy was shown to be highly effective for indolent OL, and this study represents one of the largest single-institution studies using primary RT for stage IE OL.

Entities:  

Keywords:  Lymphoma and Hodgkin disease; chemotherapeutic approaches; radiation

Mesh:

Year:  2015        PMID: 25356924     DOI: 10.3109/10428194.2014.979415

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

1.  Histopathological Features and Ann Arbor Stage in Periocular Lymphoma.

Authors:  Marco Zschoche; Annette Zimpfer; Björn O Scheef; Anselm M Jünemann; Rudolf F Guthoff; Christian Junghanss; Guido Hildebrandt; Steffen Emmert; Andreas Erbersdobler; Günther Kundt; Vinodh Kakkassery
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma.

Authors:  Chelsea C Pinnix; Bouthaina S Dabaja; Sarah A Milgrom; Grace L Smith; Zeinab Abou; Loretta Nastoupil; Jorge Romaguera; Francesco Turturro; Nathan Fowler; Luis Fayad; Jason Westin; Sattva Neelapu; Michelle A Fanale; Maria A Rodriguez; Frederick Hagemeister; Hun Ju Lee; Yasuhiro Oki; Michael Wang; Felipe Samaniego; Linda Chi; Bita Esmaeli
Journal:  Head Neck       Date:  2017-04-03       Impact factor: 3.147

3.  Clinicopathologic Characteristics Associated with Prognosis in Ocular Extranodal Marginal Zone B Cell Lymphoma.

Authors:  Soyeon Choi; Minjung Seo; Seol Hoon Park; Jae-Cheol Jo; Seoung Wan Chae; Ju-Hyang Lee; Hee Jeong Cha
Journal:  Medicina (Kaunas)       Date:  2022-06-17       Impact factor: 2.948

4.  Proton therapy in the management of non-Hodgkin lymphoma.

Authors:  Suzanne Sachsman; Stella Flampouri; Zuofeng Li; James Lynch; Nancy P Mendenhall; Bradford S Hoppe
Journal:  Leuk Lymphoma       Date:  2015-05-18

5.  Target volume dose and clinical outcome in radiotherapy for primary marginal zone lymphoma of the ocular adnexa.

Authors:  Natuhiko Shirota; Hidetsugu Nakayama; Sachica Shiraishi; Yoshihiko Usui; Keisuke Kimura; Tomohide Sanada; Norifumi Kennoki; Mitsuru Okubo; Hiroshi Goto; Koichi Tokuuye
Journal:  Mol Clin Oncol       Date:  2017-05-05

6.  Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell Lymphoma.

Authors:  Ga-In Lee; Dongryul Oh; Won Seog Kim; Seok Jin Kim; Young Hyeh Ko; Kyung In Woo; Yoon-Duck Kim; Yong Chan Ahn
Journal:  Cancer Res Treat       Date:  2017-06-16       Impact factor: 4.679

7.  Radiation Therapy Efficacy and Toxicity for Orbital and Ocular Adnexal Mucosa-Associated Lymphoid Tissue (OAMALT): A Single-Center, Retrospective Study of 32 Cases.

Authors:  Liping Xu; Xinyu Tang; Nan Jiang; Sheng Zhang; Yuandong Cao; Xinchen Sun
Journal:  Cancer Manag Res       Date:  2021-10-21       Impact factor: 3.989

8.  Chemotherapy alone is an alternative treatment in treating localized primary ocular adnexal lymphomas.

Authors:  Wei-Li Ma; Ming Yao; Shu-Lang Liao; Jih-Luh Tang; Yao-Ching Wang; Sung-Hsin Kuo; Ann-Lii Cheng
Journal:  Oncotarget       Date:  2017-06-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.